Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lasmiditan + propranolol
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lasmiditan + propranolol is a nonbranded coadministration of two pharmacological agents used in the management of migraine. **Lasmiditan** is a centrally penetrant, selective serotonin (5-HT<sub>1F</sub>) receptor agonist indicated for the acute treatment of migraine, exerting its action by inhibiting neuropeptide release and modulating pain pathways in the central nervous system without inducing vasoconstriction. **Propranolol** is a non-selective beta-adrenergic receptor antagonist ('beta-blocker') used in migraine prophylaxis and other cardiovascular indications, primarily working by reducing heart rate and cardiac output, and also decreasing renin release from the kidneys. The combination is typically considered when a patient requires both acute and prophylactic management of migraine.
02
Targets
HTR1F (Serotonin 5-HT1F receptor)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on lasmiditan + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lasmiditan + propranolol.